{"analyses":[{"ciLowerLimit":"-11.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-2.63","groupDescription":"Comparison of treatments were calculated.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.003650","paramType":"Difference","paramValue":"-6.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-7.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.75","groupDescription":"Comparison of treatments were calculated.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.019991","paramType":"Difference","paramValue":"-4.15","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1"},{"groupId":"OG001","value":"10.8"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"6.6"}]}],"title":"RECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \\< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis.","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)","title":"Objective Tumor Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of subjects"}